Data from the QUASAR long-term extension study demonstrate more than 70% of patients were in clinical remission and more than 40% of patients were in endoscopic remission at Week 92 SAN DIEGO, Calif., May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from...
Hence then, the article about tremfya guselkumab delivers sustained clinical and endoscopic remission in ulcerative colitis through two years was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years )
Also on site :
- Wharton’s great contrarian says AI adoption isn’t an easy way to cut headcount: ‘The key thing … is just how much work is involved in doing it’
- Ex-husband charged in deaths of Monique and Spencer Tepe
- A Red State’s High Court Gave Sam Alito the Dobbs Rejoinder He Deserves